Related Experiment Videos
Safety of cefotaxime and other new beta-lactam antibiotics
Abstract:
beta-Lactam antimicrobial agents have until recently enjoyed a reputation of reliability and safety. Now serious problems have emerged associated with use of some of the newer drugs of this class. Latamoxef (moxalactam) and cefoperazone, both of which have a methyltetrazolethiol side chain, have been reported to cause coagulation abnormalities, clinical bleeding, and disulfiram-like reactions. In addition, an unusually high incidence of diarrhoea has been associated with administration of cefoperazone. Cefotaxime does not have the [methylthiotetrazole] side chain and has not caused bleeding, coagulopathy, or disulfiram-like reactions. Diarrhoea, usually mild, has been observed in only 1% of patients given cefotaxime in clinical trials. The remarkable safety record of cefotaxime is an important consideration for clinicians in the selection of an antimicrobial agent for seriously ill patients.
Insights
Newer beta-lactam antibiotics like latamoxef and cefoperazone cause bleeding and disulfiram-like reactions due to their side chain. Cefotaxime, lacking this side chain, demonstrates a superior safety profile with minimal side effects, making it ideal for critically ill patients.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Medicine
Background:
- Beta-lactam antimicrobial agents have historically been considered safe and reliable.
- Emerging concerns exist regarding newer beta-lactam drugs, specifically those with a methyltetrazolethiol side chain.
- Latamoxef (moxalactam) and cefoperazone have been linked to coagulation abnormalities, bleeding, and disulfiram-like reactions.
Purpose of the Study:
- To evaluate the safety profiles of newer beta-lactam antimicrobial agents.
- To compare the adverse effects of cefotaxime against other beta-lactams with a methyltetrazolethiol side chain.
- To inform clinical selection of antibiotics for seriously ill patients based on safety data.
Main Methods:
- Review of clinical trial data and reported adverse events associated with beta-lactam antibiotics.
- Comparative analysis of side effect profiles, focusing on coagulation abnormalities, bleeding, disulfiram-like reactions, and diarrhea.
- Identification of specific structural components (methyltetrazolethiol side chain) linked to adverse events.
Main Results:
- Latamoxef and cefoperazone, possessing the methyltetrazolethiol side chain, are associated with significant coagulation issues, bleeding, and disulfiram-like reactions.
- Cefotaxime, which lacks the methyltetrazolethiol side chain, did not demonstrate these adverse effects.
- Diarrhea, a common side effect of cefoperazone, occurred in only 1% of patients receiving cefotaxime, and was typically mild.
Conclusions:
- The methyltetrazolethiol side chain in certain beta-lactam antibiotics is a key factor contributing to serious adverse events.
- Cefotaxime exhibits a significantly better safety profile compared to latamoxef and cefoperazone.
- Cefotaxime's safety record makes it a preferred choice for empirical antimicrobial therapy in critically ill patients.